Accord Healthcare Italia Srl. Pharmaceutical Import Profile — Italy (DGFT 2022–2026)

Name: Accord Healthcare Italia Srl. Pharmaceutical Import Records from India — 6 Products, $1.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Accord Healthcare Italia Srl. — Pharmaceutical Importer Profile (2026) | 6 Products, $1.4M Trade | TransData Nexus

Accord Healthcare Italia Srl.

Pharmaceutical Importer · Italy · Advanced Oncology Focus · $1.4M Total Trade · DGFT Verified

Accord Healthcare Italia Srl. is a pharmaceutical importer based in Italy with a total trade value of $1.4M across 6 products in 2 therapeutic categories. Based on 73 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Accord Healthcare Italia Srl. sources from 1 verified Indian supplier, with Intas Pharmaceuticals Limited accounting for 100.0% of imports.

Accord Healthcare Italia Srl. — Import Portfolio & Supplier Network

Accord Healthcare Italia Srl. import network — 6 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Accord Healthcare Italia Srl.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Intas Pharmaceuticals Limited	$2.8M	245	100.0%

Accord Healthcare Italia Srl. sources from 1 verified Indian supplier across 143 distinct formulations. The sourcing is highly concentrated — Intas Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Pharma drugs & medi micofenolato	$155.4K	4
Pharma drugs & medi: fulvestrant pfs	$150.0K	3
Pharma drugs & medi fulvestrant pfs	$150.0K	3
Pharma drug&med:micofenolato mofetile	$122.0K	4
Pharma drugs & medi midazolaminj5mg/ml3m	$112.1K	5
Pharma drug&med:cabazitaxel 20MG/ML	$100.0K	2
Pharma drugs & medi pelgraz 6MG/0.6ML	$100.0K	2
Pharma drugs & medi irinotecan INJ	$95.0K	9
Pharma drug&med:irinotecan INJ,20MG/ML	$91.4K	3
Pharma drug&med:quetiapine pr 50MG	$78.8K	4
Pharma drug&med:mycophe acid 360MG	$71.6K	2
Ph.dru.& med.: quetiapine pr 50MG	$70.4K	3
Pharma drug&med:vildagliptin 50MG	$66.2K	3
Pharma drugs & medi ondansetron bls	$61.0K	4
Pharma drugs & medi mycophe acid 360MG	$50.0K	1

Import Portfolio — Top 6 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Irinotecan	Oncology	$538.7K	30	1.3%	15
2	Fulvestrant	Advanced Oncology	$400.0K	8	2.7%	4
3	Cytarabine	Advanced Oncology	$257.6K	22	2.4%	9
4	Cabazitaxel	Advanced Oncology	$100.0K	2	1.1%	2
5	Fludarabine	Advanced Oncology	$73.6K	3	2.5%	9
6	Topotecan	Advanced Oncology	$70.6K	8	1.9%	9

Accord Healthcare Italia Srl. imports 6 pharmaceutical products across 2 categories into Italy totaling $1.4M.

Accord Healthcare Italia Srl. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Accord Healthcare Italia Srl, established in 2008, is a subsidiary of Accord Healthcare, a global pharmaceutical company specializing in generic medicines, biosimilars, and specialty pharmaceuticals. Headquartered in Milan, Italy, at Viale Monza 265, the company operates within the wholesale distribution sector, focusing on the import and distribution of finished pharmaceutical formulations. Accord Healthcare Italia Srl plays a significant role in Italy's pharmaceutical supply chain, providing a broad range of generic medicines to healthcare professionals and patients across the country.

2Distribution Network

While specific details about Accord Healthcare Italia Srl's warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in Milan suggests a centralized distribution model. This location facilitates efficient access to major transportation hubs, ensuring timely delivery of pharmaceutical products throughout Italy. The company's extensive product portfolio, including oncology, immunosuppressants, central nervous system (CNS) drugs, and cardiovascular and diabetes medications, indicates a well-established distribution network capable of meeting diverse healthcare needs.

3Industry Role

Accord Healthcare Italia Srl functions primarily as a pharmaceutical importer and wholesaler within Italy's supply chain. By sourcing finished pharmaceutical formulations from international manufacturers, including a significant volume from India, the company ensures a steady supply of generic medicines to the Italian market. This role is crucial in enhancing the availability and affordability of essential medications, particularly in therapeutic areas such as oncology, immunology, and cardiovascular health.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Accord Healthcare Italia Srl.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Accord Healthcare Italia Srl's sourcing strategy exhibits a high degree of concentration, with a total import value of $1.4 million USD from India across 73 shipments, primarily from a single supplier, Intas Pharmaceuticals Limited. This single-source dependency may pose risks related to supply chain disruptions, pricing fluctuations, and regulatory changes affecting the supplier. However, the consistent volume of imports and the company's established relationship with Intas Pharmaceuticals Limited suggest a stable and reliable partnership. To mitigate potential risks, it would be prudent for Accord Healthcare Italia Srl to diversify its supplier base and explore alternative sources for critical products.

2Supply Chain Resilience

The resilience of Accord Healthcare Italia Srl's supply chain is closely tied to its reliance on Intas Pharmaceuticals Limited for a substantial portion of its imports. While this partnership offers stability, it also exposes the company to risks associated with geopolitical events, regulatory changes, and supply chain disruptions in India. To enhance supply chain resilience, Accord Healthcare Italia Srl could consider establishing relationships with additional suppliers, diversifying its product formulations, and developing contingency plans to address potential disruptions. Ensuring that all suppliers adhere to recognized Good Manufacturing Practice (GMP) standards is essential for maintaining product quality and regulatory compliance.

Importing Pharmaceuticals into Italy — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Italy

1Regulatory Authority & Framework

In Italy, the Italian Medicines Agency (AIFA) serves as the primary regulatory authority overseeing the import and distribution of pharmaceutical products. The regulatory framework governing pharmaceutical imports includes the Ministerial Decree of 11 May 2001, which outlines procedures for importing medicines in case of shortages, and Legislative Decree 219/2006, which addresses the importation of parallel-imported drugs. These regulations ensure that imported medicines meet the necessary quality, safety, and efficacy standards before entering the Italian market. (aifa.gov.it)

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Italy are stringent, necessitating that all imported medicines possess marketing authorization in the country of origin and comply with EU Good Manufacturing Practice (GMP) standards. The AIFA evaluates import requests based on these criteria to ensure that imported medicines are safe and effective for the Italian population. Additionally, wholesale distribution authorization is required for entities involved in the import and distribution of pharmaceutical products within Italy. (aifa.gov.it)

3Quality & Labeling

Accord Healthcare Italia Srl. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Accord Healthcare Italia Srl's product strategy focuses on therapeutic areas with high unmet needs, such as oncology, immunology, and cardiovascular health. The company's importation of specific products like Irinotecan, Fulvestrant, Cytarabine, Cabazitaxel, and Fludarabine aligns with market demand for effective treatments in these areas. By concentrating on these therapeutic categories, Accord Healthcare Italia Srl addresses critical healthcare challenges in Italy, providing patients with access to essential generic medicines.

2Sourcing Profile

Accord Healthcare Italia Srl's sourcing strategy emphasizes the procurement of generic drugs, particularly in the oncology and immunology sectors. The company's preference for finished pharmaceutical formulations, as opposed to raw active pharmaceutical ingredients (APIs), reflects a focus on ready-to-market products that meet Italian regulatory standards. India's robust pharmaceutical manufacturing capabilities and adherence to international GMP standards make it a key supplier for Accord Healthcare Italia Srl's procurement needs.

3Market Positioning

Seller's Guide — How to Become a Supplier to Accord Healthcare Italia Srl.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Accord Healthcare Italia Srl, particularly if they can offer a diverse range of high-quality generic medicines that align with the company's therapeutic focus areas. Gaps in Accord Healthcare Italia Srl's current sourcing may include specific formulations or dosage forms not currently imported from India. By identifying and addressing these gaps, Indian exporters can enhance their competitiveness and appeal to Accord Healthcare Italia Srl.

2Requirements & Qualifications

Indian exporters seeking to supply Accord Healthcare Italia Srl must ensure that their products comply with EU GMP standards and possess the necessary marketing authorizations. Quality certifications, such as WHO GMP or PIC/S, are essential to meet regulatory requirements. Additionally, products must adhere to Italian labeling and serialization mandates to facilitate market entry and distribution.

3How to Approach

Frequently Asked Questions — Accord Healthcare Italia Srl.

What products does Accord Healthcare Italia Srl. import from India?

Accord Healthcare Italia Srl. imports 6 pharmaceutical products across 2 categories. Top imports: Irinotecan ($538.7K), Fulvestrant ($400.0K), Cytarabine ($257.6K), Cabazitaxel ($100.0K), Fludarabine ($73.6K).

Who supplies pharmaceuticals to Accord Healthcare Italia Srl. from India?

Accord Healthcare Italia Srl. sources from 1 verified Indian suppliers. The primary supplier is Intas Pharmaceuticals Limited (100.0% of imports, $2.8M).

What is Accord Healthcare Italia Srl.'s total pharmaceutical import value?

Accord Healthcare Italia Srl.'s total pharmaceutical import value from India is $1.4M, based on 73 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Accord Healthcare Italia Srl. focus on?

Accord Healthcare Italia Srl. imports across 2 categories. The largest: Advanced Oncology (62.6%), Oncology (37.4%).

Get Full Accord Healthcare Italia Srl. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.